Aurobindo Pharma subsidiary launches generic Advair Diskus in US
Aurobindo Pharma's subsidiary is adding a generic inhaler product to the US market, increasing available supply of that medicine.
Source →The trace
How it reaches your house.
Starting from Cipla, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Inhalers →Prices riseInhalation-Grade Lactose Monohydrate
A new generic inhaler launch should modestly raise demand for this critical inhaler input, creating slight upward price pressure on inhalation-grade lactose.
56% confidenceHop 2
Inhalation-Grade Lactose Monohydrate →Stands to benefitBecause inhalers are a critical use of inhalation-grade lactose, a rise in generic inhaler output should lift demand for this input and benefit DFE Pharma as a 40% supplier in a hard-to-substitute market.
71% confidenceInhalation-Grade Lactose Monohydrate →Stands to benefitBecause inhalers are a critical use of inhalation-grade lactose, a rise in generic inhaler output should lift demand for this input and benefit Meggle Pharma as a 40% supplier in a hard-to-substitute market.
71% confidenceHop 3
Meggle Pharma →Prices riseInhalation-Grade Lactose Monohydrate
More generic Advair Diskus supply should lift inhaler output and demand for this hard-to-substitute excipient, creating upward price pressure on the ingredient Meggle supplies at a 40% share.
64% confidenceDFE Pharma →Prices riseInhalation-Grade Lactose Monohydrate
A new generic Advair Diskus launch should raise demand for inhalation-grade lactose monohydrate used in inhalers, and DFE Pharma's large share plus low substitutability imply some pricing pressure.
58% confidence
Where it lands
What you buy, and what you own.
Goods you buy
No consumer goods on this path.
Companies you may own
DFE PharmaMeggle Pharma
Tap a company to see what it told the SEC could break it.
In the MyPRIA app, this is checked against your own holdings.